CHINO HILLS, CA / ACCESSWIRE / November 20, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has appointed Dr. Wei Zhu as its Senior Marketing and Sales Consultant for its biotech ABBIE division.
Mr. Baron Night, CEO of SOHM Inc., is pleased to announce the appointment of Dr. Wei Zhu as the company's Senior Marketing and Sales Consultant, effective immediately.
Dr. Zhu brings over 20 years of distinguished experience across Molecular and Cellular Biology, Biochemistry, Immunology, Signal Transduction, Cancer Biology, and Developmental Biology.
Dr. Zhu is well-recognized in the scientific community for a hands-on approach to scientific research, combined with a passion for innovation and extensive expertise in technical and strategic domains. Known for her problem-solving skills and commitment to collaboration, she excels in building bridges within and beyond scientific communities, making her an asset to both her peers and SOHM's growing team.
Dr. Zhu's technical skill set spans a broad range of high-impact areas, including Molecular Biology, Biochemistry, and Signal Transduction. Her experience also encompasses advanced Bioinformatics and Sequence-based Genomics Research, along with Histology and animal model work, making her exceptionally well-rounded in life sciences research and development. Her expertise aligns with SOHM's ongoing commitment to pioneering advancements in pharmaceutical, cosmeceutical, and nutraceutical products.
Mr. Baron Night, CEO of SOHM Inc., commented, "We are excited to welcome Dr. Zhu to SOHM. Her exceptional track record, scientific acumen, and collaborative spirit will be invaluable in driving our marketing and sales efforts forward. We look forward to her contributions as we continue to expand our footprint in the life sciences market."
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
